Aligos Therapeutics, Inc. Net Income
Aligos Therapeutics, Inc. (ALGS) reported Net Income of -$1.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:NetIncomeLoss · last filed 2026-08-06
- Aligos Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$1.50M.
- Aligos Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$23.04M, a 153.47% decline year-over-year.
- Aligos Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$19.88M.
- Aligos Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$31.54M.
- Aligos Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2025 was -$24.19M.
- Aligos Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2024 was -$131.21M.
- Aligos Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2023 was -$87.68M.
- Aligos Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2022 was -$96.05M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.50M 10-Q · filed 2026-08-06 | -$24.54M 10-Q · filed 2026-08-06 | -$44.42M derived: sum of 3 quarters · filed 2026-08-06 | -$75.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$23.04M 10-Q · filed 2026-08-06 | -$42.92M derived: sum of 2 quarters · filed 2026-08-06 | -$74.46M derived: sum of 3 quarters · filed 2026-08-06 | -$90.32M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$19.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$51.42M derived: sum of 2 quarters · filed 2026-03-05 | -$67.28M derived: sum of 3 quarters · filed 2026-08-06 | -$24.19M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$31.54M 10-Q · filed 2025-11-06 | -$47.40M derived: sum of 2 quarters · filed 2026-08-06 | -$4.31M 10-Q · filed 2025-11-06 | -$86.46M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$15.86M 10-Q · filed 2026-08-06 | $27.23M 10-Q · filed 2026-08-06 | -$54.92M derived: sum of 3 quarters · filed 2026-08-06 | -$74.18M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $43.09M 10-Q · filed 2026-08-06 | -$39.06M derived: sum of 2 quarters · filed 2026-08-06 | -$58.32M derived: sum of 3 quarters · filed 2026-08-06 | -$53.26M derived: sum of 4 quarters · filed 2026-08-06 |
| 2024-12-31 | -$82.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$101.41M derived: sum of 2 quarters · filed 2026-03-05 | -$96.35M derived: sum of 3 quarters · filed 2026-03-05 | -$131.21M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$19.26M 10-Q · filed 2025-11-06 | -$14.20M derived: sum of 2 quarters · filed 2025-11-06 | -$49.06M 10-Q · filed 2025-11-06 | -$76.95M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $5.06M 10-Q · filed 2025-11-06 | -$29.80M 10-Q · filed 2025-08-06 | -$57.69M derived: sum of 3 quarters · filed 2025-11-06 | -$75.73M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-03-31 | -$34.86M 10-Q · filed 2025-11-06 | -$62.76M derived: sum of 2 quarters · filed 2025-11-06 | -$80.80M derived: sum of 3 quarters · filed 2025-11-06 | -$99.59M derived: sum of 4 quarters · filed 2025-11-06 |
| 2023-12-31 | -$27.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$45.93M derived: sum of 2 quarters · filed 2025-03-10 | -$64.72M derived: sum of 3 quarters · filed 2025-03-10 | -$87.68M 10-K · filed 2025-03-10 |
| 2023-09-30 | -$18.04M 10-Q · filed 2024-11-06 | -$36.83M derived: sum of 2 quarters · filed 2024-11-06 | -$59.79M 10-Q · filed 2024-11-06 | -$81.67M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$18.79M 10-Q · filed 2024-08-06 | -$41.75M 10-Q · filed 2024-08-06 | -$63.63M derived: sum of 3 quarters · filed 2024-08-06 | -$82.25M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$22.95M 10-Q · filed 2024-05-07 | -$44.84M derived: sum of 2 quarters · filed 2024-05-07 | -$63.46M derived: sum of 3 quarters · filed 2024-05-07 | -$83.39M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$21.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$40.51M derived: sum of 2 quarters · filed 2024-03-12 | -$60.43M derived: sum of 3 quarters · filed 2024-03-12 | -$96.05M 10-K · filed 2024-03-12 |
| 2022-09-30 | -$18.62M 10-Q · filed 2023-11-02 | -$38.55M derived: sum of 2 quarters · filed 2023-11-02 | -$74.16M 10-Q · filed 2023-11-02 | -$111.87M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | -$19.92M 10-Q · filed 2023-08-03 | -$55.54M 10-Q · filed 2023-08-03 | -$93.25M derived: sum of 3 quarters · filed 2023-08-03 | -$126.38M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$35.62M 10-Q · filed 2023-05-04 | -$73.33M derived: sum of 2 quarters · filed 2023-05-04 | -$106.45M derived: sum of 3 quarters · filed 2023-05-04 | -$136.27M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$37.71M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$70.84M derived: sum of 2 quarters · filed 2023-03-09 | -$100.66M derived: sum of 3 quarters · filed 2023-03-09 | -$128.33M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$33.12M 10-Q · filed 2022-11-02 | -$62.94M derived: sum of 2 quarters · filed 2022-11-02 | -$90.62M 10-Q · filed 2022-11-02 | -$125.04M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | -$29.82M 10-Q · filed 2022-08-04 | -$57.49M 10-Q · filed 2022-08-04 | -$91.91M derived: sum of 3 quarters · filed 2022-08-04 | -$125.21M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$27.67M 10-Q · filed 2022-05-04 | -$62.09M derived: sum of 2 quarters · filed 2022-05-04 | -$95.39M derived: sum of 3 quarters · filed 2022-05-04 | -$116.19M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | -$34.42M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$67.72M derived: sum of 2 quarters · filed 2022-03-10 | -$88.51M derived: sum of 3 quarters · filed 2022-03-10 | -$108.54M 10-K · filed 2022-03-10 |
| 2020-09-30 | -$33.30M 10-Q · filed 2021-11-04 | -$54.09M derived: sum of 2 quarters · filed 2021-11-04 | -$74.12M 10-Q · filed 2021-11-04 | -$92.31M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | -$20.80M 10-Q · filed 2021-08-05 | -$40.83M 10-Q · filed 2021-08-05 | -$59.01M derived: sum of 3 quarters · filed 2021-08-05 | -$73.06M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | -$20.03M 10-Q · filed 2021-05-10 | -$38.21M derived: sum of 2 quarters · filed 2021-05-10 | -$52.26M derived: sum of 3 quarters · filed 2021-05-10 | |
| 2019-12-31 | -$18.18M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | -$32.23M derived: sum of 2 quarters · filed 2021-03-23 | -$52.26M 10-K · filed 2021-03-23 | |
| 2019-09-30 | -$14.05M 10-Q · filed 2020-11-25 | -$34.08M 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |